Cronos Group (CRON)
(Delayed Data from NSDQ)
$2.20 USD
-0.12 (-5.17%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $2.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CRON 2.20 -0.12(-5.17%)
Will CRON be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRON based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRON
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue Estimates
Cronos Group (CRON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CRON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Calliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains?
3 Cannabis Stocks Soaring on HHS' Recommendation to DEA
Pacira (PCRX) Lags Q2 Earnings and Revenue Estimates
Other News for CRON
Cronos Group: Caution Advised Amid Regulatory Uncertainties and Sector Re-rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cronos Group (CRON), Relay Therapeutics (RLAY) and Century Therapeutics (IPSC)
3 Cannabis Stocks That Can Be Massive Wealth Creators by 2030
CRON Stock Earnings: Cronos Group Beats Revenue for Q2 2024
Cronos Group Inc. (CRON) Q2 2024 Earnings Call Transcript